View Older Stories View More Recent Stories
-
Genmab initiates share buyback program worth up to 725 million DKK
-
Jefferies Resumes Genmab A/S (GEN:DC) (GMAB) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab reports $14.35 billion in DARZALEX sales for 2025
-
Genmab A/S (GMAB) PT Lowered to $39 at H.C. Wainwright
-
Genmab A/S (GMAB) resumes trading
-
Genmab A/S (GMAB) halted, news pending
-
Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,750 at UBS
-
Genmab partners with Anthropic to deploy AI for drug development
-
Genmab discontinues acasunlimab development to focus on late-stage programs
-
Genmab A/S (GMAB) PT Raised to $38 at Leerink Partners
-
This pharma stock has 3 'material catalysts' in 2026: BofA
-
Genmab receives FDA approval for EPKINLY combination in follicular lymphoma
-
Genmab A/S (GMAB) PT Raised to $41 at H.C. Wainwright
-
Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab launches $97 per share tender offer for Merus
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab reports DARZALEX net sales of $3.67 billion in Q3 2025
-
Genmab A/S (GMAB) PT Raised to $39 at Leerink Partners
-
Genmab A/S (GMAB) PT Raised to $49 at Truist Post MRUS Acquisition
-
Genmab A/S (GMAB) PT Raised to $49 at Truist Securities
-
Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright
-
Truist Reiterates Buy Rating on Genmab A/S (GMAB) Following MRUS Bid
-
Genmab A/S (GMAB) PT Raised to $32 at TD Cowen
-
Genmab A/S (GMAB) PT Raised to $34 at Leerink Partners
-
Guggenheim Upgrades Genmab A/S (GMAB) to Buy
-
Genmab A/S (GMAB) PT Raised to $36 at H.C. Wainwright
-
Genmab increases share capital by 4,563 shares from employee warrant exercise
-
Genmab A/S (GMAB) PT Raised to $46; Truist: 'This Stock Deserves More Appreciation'
-
Genmab A/S (GMAB) completes stock buyback plan
-
Genmab A/S (GMAB) Announces Grant of Restricted Stock Units and Warrants to Employees
-
Genmab A/S (GMAB) PT Raised to $32 at Leerink Partners
-
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK2,000 at RBC Capital on Fx Reset
-
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK17.50 at Deutsche Bank
-
Genmab A/S (GMAB) PT Lowered to $35 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab A/S (GMAB) Reports Q1 Net Sales of DARZALEX of $3.24B
-
Bernstein SocGen Group Downgrades Genmab A/S (GEN:DC) (GMAB) to Underperform
-
Genmab (GMAB) announces stock buyback program
-
Genmab (GMAB) to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (ABBV)
-
Genmab A/S (GMAB) Reports Rina-S Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
-
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK2,300 at RBC Capital
-
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK1,900 at Deutsche Bank
-
William Blair Upgrades Genmab A/S (GMAB) to Outperform
-
Genmab A/S (GMAB) PT Lowered to $45 at Truist Securities
-
Genmab A/S (GMAB): J&J will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38
-
Truist Securities Reiterates Buy Rating on Genmab A/S (GMAB)
-
Leerink Partners Upgrades Genmab A/S (GMAB) to Outperform
-
BNP Paribas Exane Upgrades Genmab A/S (GEN:DC) (GMAB) to Neutral

